Compare VanEck Semiconductor ETF (SMH) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? VanEck Semiconductor ETF trades at $553.82 (market cap $71.21B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: VanEck Semiconductor ETF is far larger — about 14.6× Travere Therapeutics Inc. Common Stock's market cap, and VanEck Semiconductor ETF is more actively traded (7,965,961 versus 1,668,577). Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 102 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SMH | TVTX | |
|---|---|---|
Market Cap | $71.21B | $4.88B |
Volume | 7,965,961 | 1,668,577 |
52-Week High | $668.91 | $67.52 |
52-Week Low | $325.10 | $26.79 |
Typical Hold Time | 102 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH, the VanEck Semiconductor ETF, trades at $564.74, down 4.44% over 24 hours amid sector volatility. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while RSI_6 at 26.18 suggests potential oversold conditions. Recent news highlights strong 2026 performance, with the ETF up around 69% year-to-date, outpacing major holdings like Nvidia, and benefiting from AI-driven semiconductor demand and industry consolidation such as AMD's acquisition of World Labs.
The outlook for SMH remains positive due to robust sector growth and AI expansion, though risks include high concentration in top holdings and sensitivity to tech sector swings. Investors should weigh the ETF's historical outperformance against potential volatility from trade tensions and macroeconomic factors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
